Nature Communications (Mar 2021)
Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2
- Hanjun Zhao,
- Kelvin K. W. To,
- Hoiyan Lam,
- Xinxin Zhou,
- Jasper Fuk-Woo Chan,
- Zheng Peng,
- Andrew C. Y. Lee,
- Jianpiao Cai,
- Wan-Mui Chan,
- Jonathan Daniel Ip,
- Chris Chung-Sing Chan,
- Man Lung Yeung,
- Anna Jinxia Zhang,
- Allen Wing Ho Chu,
- Shibo Jiang,
- Kwok-Yung Yuen
Affiliations
- Hanjun Zhao
- State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- Kelvin K. W. To
- State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- Hoiyan Lam
- Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- Xinxin Zhou
- Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- Jasper Fuk-Woo Chan
- State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- Zheng Peng
- Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- Andrew C. Y. Lee
- Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- Jianpiao Cai
- Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- Wan-Mui Chan
- Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- Jonathan Daniel Ip
- Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- Chris Chung-Sing Chan
- Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- Man Lung Yeung
- State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- Anna Jinxia Zhang
- State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- Allen Wing Ho Chu
- Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- Shibo Jiang
- Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University
- Kwok-Yung Yuen
- State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- DOI
- https://doi.org/10.1038/s41467-021-21825-w
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 9
Abstract
Until today effective antivirals for COVID-19 treatment are not widely available. Here, Zhao et al. characterize a dual-functional cross-linking peptide, 8P9R, that can inhibit SARS-CoV-2 virus entry in vitro and suppresses viral replication in vivo in golden Syrian hamster.
